| related words |
| deadline |
| bayer |
| genentech |
| pfizer |
| endpoint |
| insulin |
| announce |
| hematide |
| tm |
| clinically |
| riquent |
| gsk |
| xr |
| receptive |
| hcv |
| factive |
| predictive |
| forming |
| commercialized |
| validated |
|
| related documents |
| 820237--2/25/2009--GEN_PROBE_INC |
| 1017491--3/26/2007--NEXMED_INC |
| 1347178--3/15/2010--Vanda_Pharmaceuticals_Inc. |
| 706539--3/16/2006--CHIRON_CORP |
| 805326--3/25/2010--EMISPHERE_TECHNOLOGIES_INC |
| 815838--3/13/2009--NOVEN_PHARMACEUTICALS_INC |
| 1093649--3/4/2009--IDENIX_PHARMACEUTICALS_INC |
| 805326--3/16/2009--EMISPHERE_TECHNOLOGIES_INC |
| 815838--4/1/2008--NOVEN_PHARMACEUTICALS_INC |
| 815838--3/12/2007--NOVEN_PHARMACEUTICALS_INC |
| 1093649--3/14/2008--IDENIX_PHARMACEUTICALS_INC |
| 820237--2/25/2008--GEN_PROBE_INC |
| 1099414--3/16/2007--TANOX_INC |
| 1017491--3/12/2008--NEXMED_INC |
| 820237--2/23/2007--GEN_PROBE_INC |
| 1093649--3/14/2007--IDENIX_PHARMACEUTICALS_INC |
| 874015--3/16/2007--ISIS_PHARMACEUTICALS_INC |
| 1128495--3/15/2007--ANADYS_PHARMACEUTICALS_INC |
| 815838--3/15/2006--NOVEN_PHARMACEUTICALS_INC |
| 1017491--3/16/2006--NEXMED_INC |
|
| related topics |
| {product, candidate, development} |
| {interest, director, officer} |
| {provision, law, control} |
| {control, financial, internal} |
| {stock, price, operating} |
| {product, liability, claim} |
| {debt, indebtedness, cash} |
| {acquisition, growth, future} |
| {customer, product, revenue} |
| {tax, income, asset} |
| {investment, property, distribution} |
| {regulation, change, law} |
| {financial, litigation, operation} |
| {competitive, industry, competition} |
| {stock, price, share} |
| {regulation, government, change} |
| {personnel, key, retain} |
| {cost, operation, labor} |
| {system, service, information} |
| {capital, credit, financial} |
|